Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction

Journal of Urology

Volumn 184, Issue 2, 2010, Pages 783-789

  Fllhase, Claudius ^a,b   Soler, Roberto ^a,c   Gratzke, Christian ^b   Brodsky, Marina ^d   Christ, George J ^a   Andersson, Karl Erik ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d PFIZER INC   (United States)

Author keywords

adrenergic alpha antagonists; doxazosin; fesoterodine; muscarinic antagonists; prostatic hyperplasia

Indexed keywords

DOXAZOSIN; FESOTERODINE; TOLTERODINE;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; BLADDER; BLADDER CATHETERIZATION; BLADDER FUNCTION; BLADDER PRESSURE; BRAIN; CATHETERIZATION; CONTROLLED STUDY; DRUG EFFECT; MALE; METABOLITE; MICTURITION; NONHUMAN; ORGAN WEIGHT; PARAMETER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; SPINE; SPRAGUE DAWLEY RAT; UPREGULATION; URETHRA OBSTRUCTION; URINARY FREQUENCY; URINARY TRACT; URODYNAMICS;

EID: 77955466240     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.03.104     Document Type: Article

References (26)

1. S.A. Kaplan, C.G. Roehrborn, and E.S. Rovner Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial JAMA 296 2006 2319
2. J.Y. Lee, H.W. Kim, and S.J. Lee Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder BJU Int 94 2004 817
3. Y. Yang, X.F. Zhao, and H.Z. Li Efficacy and safety of combined therapy with terazosin and tolterodine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study Chin Med J (Engl) 120 2007 370
4. D.R. Staskin, M.T. Rosenberg, and N.V. Dahl Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions Int J Clin Pract 62 2008 27
5. D.E. Irwin, I. Milsom, and S. Hunskaar Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study Eur Urol 50 2006 1306
6. C.R. Chapple, A.J. Wein, and P. Abrams Lower urinary tract symptoms revisited: a broader clinical perspective Eur Urol 54 2008 563
7. P. Abrams, and K.E. Andersson Muscarinic receptor antagonists for overactive bladder BJU Int 100 2007 987
8. K.E. Andersson, and C. Gratzke Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system Nat Clin Pract Urol 4 2007 368
9. K.E. Andersson LUTS treatment: future treatment options Neurourol Urodyn 26 2007 934
10. K.E. Andersson, and R. Pehrson CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention Drugs 63 2003 2595
11. O. Ishizuka, K. Persson, and A. Mattiasson Micturition in conscious rats with and without bladder outlet obstruction: role of spinal alpha 1-adrenoceptors Br J Pharmacol 117 1996 962
12. P. Ney, R.K. Pandita, and D.T. Newgreen Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo BJU Int 101 2008 1036
13. A. Melman, M. Tar, and J. Boczko Evaluation of two techniques of partial urethral obstruction in the male rat model of bladder outlet obstruction Urology 66 2005 1127
14. A. Malmgren, C. Sjogren, and B. Uvelius Cystometrical evaluation of bladder instability in rats with infravesical outflow obstruction J Urol 137 1987 1291
15. T.L. Yaksh, and T.A. Rudy Chronic catheterization of the spinal subarachnoid space Physiol Behav 17 1976 1031
16. O. Ishizuka, A. Mattiasson, and W.D. Steers Effects of spinal alpha 1-adrenoceptor antagonism on bladder activity induced by apomorphine in conscious rats with and without bladder outlet obstruction Neurourol Urodyn 16 1997 191
17. A. Schrder, B. Uvelius, and D. Newgreen Bladder overactivity in mice after 1 week of outlet obstruction Mainly afferent dysfunction? J Urol 170 2003 1017
18. J.L. Mostwin, O.M. Karim, and G. van Koeveringe The guinea pig as a model of gradual urethral obstruction J Urol 145 1991 854
19. Y. Ishiura, M. Yoshiyama, and O. Yokoyama Central muscarinic mechanisms regulating voiding in rats J Pharmacol Exp Ther 297 2001 933
20. H. Masuda, M.B. Chancellor, and K. Kihara Effects of cholinesterase inhibition in supraspinal and spinal neural pathways on the micturition reflex in rats BJU Int 2009
21. O. Ishizuka, R.K. Pandita, and A. Mattiasson Stimulation of bladder activity by volume, L-dopa and capsaicin in normal conscious ratseffects of spinal alpha 1-adrenoceptor blockade Naunyn Schmiedebergs Arch Pharmacol 355 1997 787
22. M. Trevisani, B. Campi, and R. Gatti The influence of alpha1-adrenoreceptors on neuropeptide release from primary sensory neurons of the lower urinary tract Eur Urol 52 2007 901
23. O. Yokoyama, A. Yusup, and N. Oyama Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats Neurourol Urodyn 25 2006 461
24. P.A. Durant, P.C. Lucas, and T.L. Yaksh Micturition in the unanesthetized rat: spinal vs. peripheral pharmacology of the adrenergic system J Pharmacol Exp Ther 245 1988 426
25. C. Fullhase, R. Soler, and M. Brodsky Effects of fesoterodine, a novel antimuscarinic, alone and in combination with an α-receptor blocker, doxazosin, on bladder function in obstructed rats J Urol 181 2009 697
26. G. Kay, B. Malhotra, and M.C. Michel Assessment of central nervous system access of a new antimuscarinic drug, fesoterodine J Urol 181 2009 84